We use cookies for a better user experience. Read our Privacy Policy

I Agree

Asthma and COPD Drugs Market

Asthma and COPD Drugs Market (Drug Class - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs; Indication - Asthma and COPD) - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

U.S. and China Asthma and COPD Drugs Market: Snapshot

The U.S. and China market for asthma and chronic obstructive pulmonary disease (COPD) drugs is expected to exhibit growth at a steady pace in the next few years. Factors such as a significant rise prevalence of COPD and asthma in these two countries, advancements in diagnostic methods, and rising awareness among patients regarding the available treatment methods are considered key to the overall growth of the market over the period 2016–2024.

The market is expected to exhibit growth at a moderate pace in the first few years of the forecast period, chiefly owing to the patent expiries of leading drugs and the subsequent price erosion. However, the market is expected to witness new drug candidates by 2020, which will help the market tread along a better growth path in the forthcoming years.

Transparency Market Research estimates that the market will exhibit a 4.1% CAGR from 2016 through 2024, rising to a valuation of US$18.7 bn by 2024 from US$13.0 bn in 2015.

Combination Drugs Sales to Constitute Bulk of Revenue

On the basis of drug classes in the U.S. and China asthma and COPD drugs market, the report examines the future scope of growth for varieties such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs.

Of these, the segment of combination drugs is presently the leading segment. It accounted for a 54% of the U.S. and China asthma and COPD drugs market in 2015 and is expected to continue to dominate throughout the report’s forecast period. Combination drugs benefit from the recommendations from agencies such as Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Global Initiative for Asthma (GINA), which regard combination drugs as the safer course of managing asthma and COPD.

The segment of monoclonal antibodies is expected to emerge as a prominent drug class for the management of asthma and COPD in the next few years. Emergence of new drug candidates in this segment will bolster its growth potential in the market during the report’s forecast period.

us china asthma copd drugs market

High Costs of Asthma and COPD Drugs and Consumer Awareness make U.S. the Clear Leader

In the U.S. and China market for asthma and COPD drugs, the U.S. market clearly dominates, accounting for a more than 81% of the overall market in 2016. The key factors to have benefitted the U.S. market, despite it being a relatively smaller market in terms of population, include the high costs of asthma and COPD drugs and a high level of attentiveness paid by consumers to healthcare and wellness. The U.S. market also contributes significantly to the overall asthma and COPD drugs market through regular product launches and high investments by leading companies for R&D in the areas of combination therapies and biologics.

Although China presently accounts for a relatively smaller share in the U.S. and China asthma and COPD drugs market, the country is expected to present attractive growth opportunities in the next few years. The China market for asthma and COPD drugs will exhibit an impressive 10% CAGR over the period between 2016 and 2024. The key factors attributable to this projection are the rising number of asthma patients, owing chiefly to rising levels of air pollution, and a vast array of unmet medical needs.

The rising prevalence of COPD in the country is chiefly owing to the high and rising number of smokers. The China market for asthma and COPD drugs also comes across as a more attractive market than the U.S. market owing to a low level of competition and high rate of growth.

Some of the leading vendors presently operating in the U.S. and China asthma and COPD drugs market profiled in the report are Boehringer Ingelheim, GlaxoSmithKline plc, Merck and Co., Inc., Novartis AG, AstraZeneca plc, and F. Hoffmann-La Roche.

Asthma and COPD Drugs Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: U.S. and China Asthma and COPD Drugs Market

Chapter 4. Market Overview
4.1. Introduction 
4.2. Key Industry Developments
4.3. Market Dynamics
      4.3.1. Drivers
      4.3.2. Restraints
      4.3.3. Opportunity
4.4. Porter’s Five Forces Analysis

Chapter 5. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Drug Class
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Drug Class
      5.3.1. Bronchodilators
               5.3.1.1. Short Acting Beta-2 Agonists 
               5.3.1.2. Long Acting Beta-2 Agonists
               5.3.1.3. Anti-cholinergic Agents 
      5.3.2. Anti-inflammatory Drugs
               5.3.2.1. Oral and Inhaled Corticosteroids
               5.3.2.2. Anti-leukotrienes
               5.3.2.3. Phosphodiesterase Type-4 Inhibitors
               5.3.2.4. Others
      5.3.3. Monoclonal Antibodies
      5.3.4. Combination Drugs
5.4. Market Attractiveness Analysis, by Drug Class, 2015
5.5. Key Trends

Chapter 6. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Indication
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Indication
      6.3.1. Asthma
      6.3.2. COPD
6.4. Market Attractiveness Analysis, by Indication, 2015
6.5. Key Trends

Chapter 7. U.S. and China Asthma and COPD Drugs Market Analysis and Forecast, By Region
7.1. Market Scenario
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
      7.3.1. U.S.
      7.3.2. China
7.4. Market Attractiveness Analysis, by Region, 2015

Chapter 8. U.S. Asthma and COPD Drugs Market Analysis and Forecast 
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Drug Class
      8.3.1. Bronchodilators
               8.3.1.1. Short Acting Beta-2 Agonists 
               8.3.1.2. Long Acting Beta-2 Agonists
               8.3.1.3. Anti-cholinergic Agents 
      8.3.2. Anti-inflammatory Drugs
               8.3.2.1. Oral and Inhaled Corticosteroids
               8.3.2.2. Anti-leukotrienes
               8.3.2.3. Phosphodiesterase Type-4 Inhibitors
               8.3.2.4. Others
      8.3.3. Monoclonal Antibodies
      8.3.4. Combination Drugs
8.4. Market Size (US$ Mn) Forecast, by Indication
      8.4.1. Asthma
      8.4.2. COPD
      8.4.3. Canada
8.5. Market Attractiveness Analysis, by Drug Class, 2015
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Key Trends

Chapter 9. China Asthma and COPD Drugs Market Analysis and Forecast 
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Drug Class
      9.3.1. Bronchodilators
               9.3.1.1. Short Acting Beta-2 Agonists 
               9.3.1.2. Long Acting Beta-2 Agonists
               9.3.1.3. Anti-cholinergic Agents 
      9.3.2. Anti-inflammatory Drugs
               9.3.2.1. Oral and Inhaled Corticosteroids
               9.3.2.2. Anti-leukotrienes
               9.3.2.3. Phosphodiesterase Type-4 Inhibitors
               9.3.2.4. Others
      9.3.3. Monoclonal Antibodies
      9.3.4. Combination Drugs
9.4. Market Size (US$ Mn) Forecast, by Indication
      9.4.1. Asthma
      9.4.2. COPD
      9.4.3. Canada
9.5. Market Attractiveness Analysis, by Drug Class, 2015
9.6. Market Attractiveness Analysis, by Indication, 2015
9.7. Key Trends

Chapter 10. Competition Landscape
10.1. Global Asthma and COPD Drugs Market Share Analysis, Key Players, 2015
10.2. Competition Matrix
10.3. Company Profiles
      10.3.1. AstraZeneca plc
               10.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.1.2. Financial Overview
               10.3.1.3. Product Portfolio
               10.3.1.4. SWOT Analysis
               10.3.1.5. Strategic Overview
      10.3.2. Boehringer Ingelheim GmbH
               10.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.2.2. Financial Overview
               10.3.2.3. Product Portfolio
               10.3.2.4. SWOT Analysis
               10.3.2.5. Strategic Overview
      10.3.3. F Hoffmann-La Roche Ltd.
               10.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
               10.3.3.2. Financial Overview
               10.3.3.3. Product Portfolio
               10.3.3.4. SWOT Analysis
      10.3.4. GlaxoSmithKline plc
               10.3.4.1. Company Overview (HQ, business segments, employee strength)
               10.3.4.2. Financial Overview
               10.3.4.3. Product Portfolio
               10.3.4.4. SWOT Analysis
               10.3.4.5. Strategic Overview
      10.3.5. Merck & Co., Inc.
               10.3.5.1. Company Overview (HQ, business segments, employee strength)
               10.3.5.2. Product Portfolio
               10.3.5.3. SWOT Analysis
               10.3.5.4. Recent Developments
               10.3.5.5. Strategic Overview
      10.3.6. Novartis AG
               10.3.6.1. Company Overview (HQ, business segments, employee strength)
               10.3.6.2. Financial Overview
               10.3.6.3. Product Portfolio
               10.3.6.4. SWOT Analysis
               10.3.6.5. Strategic Overview

List of Tables

Table 1: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 2: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024
Table 3: U.S. and China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Region, 2014–2024
Table 4: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 5: U.S. Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication Type, 2014–2024
Table 6: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Drug Class, 2014–2024
Table 7: China Asthma and COPD Drugs Market Size Analysis and Forecast (US$ Mn), by Indication, 2014–2024

List of Figures

Figure 1: U.S. and China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 2: U.S. and China Asthma and COPD Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 3: U.S. and China Bronchodilators Market Revenue (US$ Mn), 2014–2024
Figure 4: U.S. and China Anti-inflammatory Drugs Market Revenue (US$ Mn), 2014–2024
Figure 5: U.S. and China Monoclonal Antibodies Market Revenue (US$ Mn), 2014–2024
Figure 6: U.S. and China Combination Drugs Market Revenue (US$ Mn), 2014–2024
Figure 7: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Drug Class, 2015
Figure 8: U.S. and China Asthma and COPD Drugs Value Share Analysis, by Indication, 2016 and 2024
Figure 9: U.S. and China Asthma Market Revenue (US$ Mn), 2014–2024
Figure 10: U.S. and China COPD Market Revenue (US$ Mn), 2014–2024
Figure 11: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Indication, 2015
Figure 12: Global U.S. and China Asthma and COPD Drugs Value Share Analysis, by Region, 2016 and 2024
Figure 13: U.S. and China Asthma and COPD Drugs Attractiveness Analysis, by Region, 2015
Figure 14: U.S. Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 15: U.S. Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 16: U.S. Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 17: U.S. Market Value Share Analysis, by Indication, 2016 and 2024
Figure 18: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 19: U.S. Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 20: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: U.S. Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 22: China Asthma and COPD Drugs Market Size (US$ Mn), 2014–2024
Figure 23: China Asthma and COPD Drugs Market Y-o-Y Growth Projections, 2015–2024
Figure 24: China Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 25: China Market Value Share Analysis, by Indication, 2016 and 2024
Figure 26: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Drug Class, 2014–2024
Figure 27: China Asthma and COPD Drugs Market Analysis and Forecast, US$ Mn, by Indication, 2014–2024
Figure 28: China Asthma and COPD Drugs Market Attractiveness Analysis, by Drug Class, 2015
Figure 29: China Asthma and COPD Drugs Market Attractiveness Analysis, by Indication, 2015
Figure 30: Global Asthma and COPD Drugs Market Share Analysis, by Company (2015)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

544

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved